Real-world outcomes of venetoclax plus hypomethylating agents in unfit acute myeloid leukaemia: Results of the GIMEMA AML2320 trial.
A commonly used leukemia treatment delivers real-world survival results matching those from rigorous clinical trials in elderly patients unfit for intensive therapy.
Venetoclax (VEN) plus hypomethylating agents (HMAs) represents the standard of care for newly diagnosed acute myeloid leukaemia (AML) patients unfit for intensive chemotherapy, but prospective real-world observational data outside randomized clinical trials remain limited. The Gruppo Italiano Malattie Ematologiche dell'Adulto (GIMEMA) AML2320 is a prospective, multicentre, observational study (NCT04589728) including 193 newly diagnosed unfit AML patients receiving VEN plus azacitidine or decitabine between November 2020 and December 2021.
What the study was
- Study design
- Clinical Trial
- Population
- Adult patients
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- British journal of haematology
Why it surfaced
Score 7/10: Clinical Trial, human model, Validated; flag=PROMISING_PRELIMINARY
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.